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N14th International Congress on Infectious Diseases (ICID) Abs
Chronic intoxication causes abnormal thyroid function and
various neurological disorders.
doi:10.1016/j.ijid.2010.02.1513
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Epidemiology of Chronic Viral Hepatitis in Latin America
D. Diament
Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil
Chronic viral hepatitis caused by Hepatitis B or C viruses
are major health problems in this beginning of the 21st
century. Estimated prevalence in the world population in
different regions range between less than 1% to more than
3% for HCV and between less than 2% to more than 8% for
HBV, affecting more than 400 million people in the world. In
Latin America, prevalence estimates are ﬂawed. For HCV it
varies from less than 1% to 2%, and for HBV from less than
1% to more than 8%. Numbers can be as high as 15% in the
Amazon region.
In Latin America, some surveys report HBV prevalence
as high as 21.4% in Dominican Republic and 7.9% in Brazil,
followed by 3.2% in Venezuela and 2.1% in Argentina. Low
prevalence was found in Mexico (1.4%) and Chile (0.6%). For
HCV, rough estimates project more than 10 million infected
people. Many surveys were conducted by blood banks, but
results are biased by sampling problems.
In Brazil, HCV prevalence studies estimates had found a
wide range, varying from 0.4% to 5.9%. A population based
study in 2007 found a HCV antibodies prevalence of 0.28%
to 2.61% and a HCV-RNA from 0.02% to 0.9% in different
regions of the country. From 1994 to 2005, the Ministry of
Health database has registered 52,440 HCV cases. Recently,
a national survey was conducted by the Ministry of Health,
but results are not published yet.
In São Paulo state, there were 30,299 HCV cases regis-
tered from 2002 to 2008 and 14,810 HBV cases in the same
period. In the city of São Paulo it is estimated a mean
prevalence of 1.42% (95% conﬁdence interval 0.7 — 2.12%).
Diagnosis can be done with blood tests, but availability is a
concern in poor countries.
Treatment is expensive and fairly effective, implying in
high morbidity, mortality and costs. Chronic hepatitis is a
great challenge for the health systems in Latin America.
doi:10.1016/j.ijid.2010.02.1514
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Update on Hepatits B Therapy
E. Savio
Universidad de la Repùblica, Montevideo, Uruguay
Tha main goal for the treatment of chronic hepatitis
B (CHB) is to prevent advanced hepatic disease: cirro-
sis,hepatic failure and hepatocellular carcinoma (HCC).
The ﬁrst aim of treatment is to achieve sustained suppre-
sion of HBV replication as well as the remission of liver
disease.The sustained supression of virological replication
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aries widely,depending on the population on treatment,
herapeutic agent s, treatment duration and less clearly
rom genotype. Since 1992,eigth therapeutic agents have
een approved worlwide (INF alfa, lamivudine, adefovir,
ntecavir, PegINF alfa-2a thymosin alfa1, ,telvibudine and
enofovir) but only some of them are used in different coun-
ries according to national regulation.. When and how to
reat an CHB depends on the HBV DNA levels, ALT and status
f HBeAg. For HBeAg(+) patients,the endpoint of treatment
s HBeAg seroconvertion. Therapy is considered in GHB with
BV DNA leves of 20.000 IU/ml or higer (HBeAg positive
atient) or 2.000 IU/ml (HBeAg negative), although lower
BV DNA levels migth be selected when evidences of pro-
resive disease are identiﬁed. ALT normalization and HBV
NA suppression are the measures of reponse to therapy.
ral nucleoside analogs (NA) is a signiﬁcant contribution for
reatment in the last years,but a major concern with this
gents is the selection of antiviral resistant mutations. This
ay be identiﬁed prior to virological breakthrough or at the
ame time. Peginterferon alfa-2a, entecavir and tenofovir
re currently included in the ﬁrst-line treatment choice on
he basis of their potency as well as the low rate of antiviral
rug resistance. The strategy of drugs combination in CHB
reatment for achieving a sustained virological response and
ome end points has beeen explored and the level of HBV
NA suppression. This combination theraphy is encouraging
n some clinical trials.
oi:10.1016/j.ijid.2010.02.1515
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epatitis C Treatment Today and the Future
. Sarmento e Castro
Hospital Joaquim Urbano, Porto, Portugal
Therapy of chronic HCV infection is based on the use
f the combination of pegylated interferon and ribavirin.
ustained virological response (SVR), a negative HCV RNA
4 weeks following discontinuation of therapy, is the most
mportant surrogate parameter to achieve. Actually, SVR is
btained in about 50% of patients with genotypes 1/4 and in
0% of the patients with genotypes 2/3.
Patients infected with genotypes 1 or 4 must be treated
or 48 weeks. But, if the patient achieves a rapid virological
esponse (RVR), deﬁned as a negative HCV RNA at week 4, we
an consider a shortening of treatment. In patients with a
low response to treatment (HCV RNA only negative between
eeks 12 and 24) the length of therapy must be extended
o 72 weeks. For patients infected with genotypes 2 or 3
reatment should be planned for 24 weeks.
New drugs are needed for non-responders and for those
ho are not good candidates to treatment.
Several new oral agents, more potent, less toxic and
llowing for shorter duration of treatment are being devel-
ped. These new drugs are designed to inhibit several viral
nzymes. Results of recent clinical trials using inhibitors of
S3/4A protease or inhibitors of NS5B polymerase in com-
ination with peginterferon/ribavirin are promising. These
tudies demonstrated that adding telaprevir or boceprevir
the protease inhibitors in the most advanced phases of eval-
ation) to peginterferon/ribavirin improved the rates of SVR
